Mesoblast Ltd (ASX:MSB) (NASDAQ:MESO) shares are up 6.7% today to $1.11 after it provided a summary of the status of its product portfolio and the developments expected to take place in 2019.
The company researches and develops biologic products for regenerative medicine.
It focuses on adult mesenchymal precursor cells (MPCs), mesenchymal stem cells (MSCs), dental pulp cells and adipose cells.
Mesoblast will enter 2019 with the most mature cell therapy product pipeline and technology platform in the regenerative medicine industry.
Upcoming milestones in 2019
Remestemcel-L for acute graft versus host disease
- FDA meetings and BLA filing (Early CY19).
Revascor for end-stage heart failure
- Meet with FDA to discuss the clinically meaningful GI bleeding Phase 2 trial data for potential BLA filing (1H CY19).
Phase III events-driven trial in advanced heart failure
- Complete recruitment (Q4 CY18/Q1 CY19);
- Cardiovascular partner Tasly Pharmaceuticals to meet with National Medical Products, administration to discuss the regulatory approval pathway in China (Q1 CY19); and
- Establish global partnership.
MPC-06-ID for chronic low back pain
- Establish global partnership